sb 203580 has been researched along with lycopene in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (lycopene) | Trials (lycopene) | Recent Studies (post-2010) (lycopene) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 3,078 | 274 | 1,634 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, RD; Feng, D; Ling, WH | 1 |
1 other study(ies) available for sb 203580 and lycopene
| Article | Year |
|---|---|
Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-kappaB in macrophages.
Topics: Animals; Antioxidants; Butadienes; Carotenoids; Cell Line; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; I-kappa B Kinase; Imidazoles; Interleukin-6; Lipopolysaccharides; Lycopene; Macrophages; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-kappa B; Nitric Oxide; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Signal Transduction; Tumor Necrosis Factor-alpha | 2010 |